CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Wang Xiaolin See Remarks | Grant or award | +24,200 | 84,526 | ||
| 2024-03-01 | Wang Xiaolin See Remarks | Grant or award · Stock Option (Right to Buy) | +84,700 | 84,700 | ||
| 2024-01-22 | Cislini Jeff General Counsel | Sale 10b5-1 | −1,500 | $27.00 | $41K | 36,126 |
| 2024-01-08 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −3,337 | $29.01 | $97K | 221,632 |
| 2024-01-02 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −13,330 | $29.10 | $388K | 224,969 |
| 2023-12-27 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −33,334 | $29.01 | $967K | 238,299 |
| 2023-12-18 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −1,775 | $25.90 | $46K | 76,416 |
| 2023-12-18 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −8,165 | $25.90 | $211K | 376,167 |
| 2023-12-18 | Cislini Jeff General Counsel | Sale 10b5-1 | −1,229 | $25.90 | $32K | 37,284 |
| 2023-12-18 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −2,088 | $25.90 | $54K | 271,633 |
| 2023-12-18 | Horn Margaret A Chief Operating Officer | Sale 10b5-1 | −2,993 | $25.90 | $78K | 101,467 |
| 2023-12-15 | Horn Margaret A Chief Operating Officer | Option exercise 10b5-1 | +5,000 | $4.09 | $20K | 109,460 |
| 2023-12-15 | Horn Margaret A Chief Operating Officer | Sale 10b5-1 | −5,000 | $26.64 | $133K | 104,460 |
| 2023-12-15 | Horn Margaret A Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 68,302 | ||
| 2023-12-06 | Horn Margaret A Chief Operating Officer | Option exercise 10b5-1 | +5,000 | $4.09 | $20K | 109,460 |
| 2023-12-06 | Horn Margaret A Chief Operating Officer | Sale 10b5-1 | −5,000 | $25.00 | $125K | 104,460 |
| 2023-12-06 | Horn Margaret A Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 73,302 | ||
| 2023-11-20 | Cislini Jeff General Counsel | Sale 10b5-1 | −1,500 | $21.70 | $33K | 38,513 |
| 2023-11-09 | Horning Sandra Director | Grant or award | +52,291 | 52,291 | ||
| 2023-11-09 | Horning Sandra Director | Grant or award | +27,696 | 79,987 |
Page 28 of 29 · 569 trades